Anthrax and other Microbial Threats

World Health Organisation Report on Infectious Diseases. Removing obstacles to healthy development (available at http://www.who.int/infectious-disease-report)

Task force on E.coli O157. Final report. June 2001. Scottish Executive. HM Stationary office (available at http://www.scotland.gov.uk/library3/health/ecoli.pdf).

Pittet D Hugonnet S Harbarth S . Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet 2000; 356: 1307–1312.

Breman J G Henderson D A . Poxvirus dilemmas: Monkeypox, smallpox and biological terrorism. N Eng J Med. 1998; 339: 556–559.

Inglesby T V Dennis D T Henderson D A . Plague as a biological weapon: Medical and public health management. JAMA 2000; 283: 2281–2290.

Franz D R Jahrling P B Friedlander A M . Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399–403.

Christopher G W Cielak T J Pavlin J A Eitzen E M . Biological warfare: A historical perspective. JAMA 1997; 278: 412–417.

Cole L A . The spectre of biological weapons. Sci Am 1996: 275: 60–65.

Meselson M Guillemin J Hugh-Jones M . The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266: 202–1208.

Manchee R J Brosler M G Anderson I S Henstridge R M Melling J . Decontamination of B. anthracic on Gruinard Island. Nature 1983; 303: 239–240.

Kaufmann A F Meltzler M I Schmid G P . The economic impact of a bioterrorist attack. Emerging Infect Dis 1997; 3: 83–94.

Hanna P . How anthrax kills. Science 1998; 280: 1671.

Fraser C Dando M . Genomics and future biological weapons: The need for preventative action by the biomedical community. Nature Genetics; 2001: 29: 253–256.

Anthrax as a biological weapon: Medical and Public Health Management. JAMA 1999; 281: 1735–1745.

Hanna P C Acosta D Collier R J . On the role of macrophages in anthrax. Proc Natl Acad Scl USA 1993; 90: 10198–10201.

Leppla S H . The anthrax toxin complex. In: Alouf J Freer J H eds. Sourcebook of bacterial protein toxins. London: Academic Press, 1991: 277–302.

O'Brien J Freidlander A Dreier T Ezzell J Leppla S . Effects of anthrax toxin components on human neutrophils. Infect Immunol 1985; 47: 306–10.

Duesbery N S Webb C P Leppla S H . Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998; 280: 734–7.

Hanna P C Kochi S Collier R J . Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells. Mol Biol Cell 1992; 3: 1269–77.

Dai Z Sirard J-C Mock M Koehler T M . The atxA gene product actitates transcription of the anthrax toxin genes and is essential for virulence. Mol Microbiol 1995; 16: 1171–81.

Dai Z Koehler T M . Regulation of anthrax toxin activator gene (atx) expression in Bacillus anthracis: Temperature, not CO2/bicarbonate, affects AtxA synthesis. Infect Immunol 1997; 65: 2576–82.

Turnbull P C . Anthrax vaccines: Past, present and future. Vaccine 1991; 9: 533–539.

Mourez M Kane R Mogridge J Metallo S Daschatelets P Sellman B Whitesides G . Collier Designing a polyvalent inhibitor of anthrax toxin. Nature Biotechnology 2001; 19: 958–961.

Jernigan J A Stephens D S Ashford D A . Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerging Infect Dis 2001; 7: 933–944.

Abramova F A Grinberg L M Yampolskaya O V Walker D H . Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA 1993; 90: 2291–2294.

CDC. Update: Investigation of bioterrorism-related inhalational anthrax-Connecticut, 2001. MMWR; 2001; 50: 1049–1051.

Patra G Vaissaire J Weber-Levy M Le Doujet C Mock M . Molecular characterisation of Bacillus strains involved in outbreaks of anthrax in France in 1997. J Clin Microbiol 1998; 36: 3412–4.

Turnbull P C . Definitive identification of Bacillus anthracis — a review J Appl Microbiol 1999; 87; 237–40.

Shylakhov E Rubenstein E . Evaluation of the anthraxin skin test for diagnosis of acute and past human anthrax. Eur J Clin Microbiol Infect Dis 1996; 15: 242–5.

Eagle H . Experimental approach to the problem of treatment failure with penicillin. I. Group A Streptococcal infection in mice. Am J Med 1952; 13: 389–399.

Gemmell C G Peterson P K Schmeling D . Potentiation of opsonisation and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981; 67: 1249–1256.

Swartz M N . Recognition and Management of Anthrax- an update. N Eng J Med 2001; 345: 1621–1626.

Turnbull P C . Anthrax vaccines: Past, present and future. Vaccine 1991; 9: 533–539.

Bradley K Mogridge J Mourez M Collier J Young J . Identification of the cellular receptor for anthrax toxin. Nature 2001; 414: 225–229.

Pannifer A Wong T Y Schwarzenbacher R Renatus M Petosa C Bienkowska J Lacy D B Collier J Park S Leppla S Hanna P Liddington R . Crystal structure of the anthrax lethal factor. Nature 2001; 414: 229–233.

Watters J W . Kifc, a kinesin-like motor protein, mediates mouse macrophages resistance to anthrax lethal factor. Current Biology, 2001; 11: 1503–1511.

Torok T J Tauxe R V Wise R P . A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA 1997; 287: 384–395.

Hart C A Beeching N . Prophylactic treatment of anthrax with antibiotics. Br Med J; 2001; 323: 1017–1018.

Fox J . Adjusting FDA policies to address bioterrorist threat. Business and regulatory news. 1999; 17: 323–324.

Cohen H W Sidel V W Gould R M . Preparedness for Bioterrorism? N Eng J Med; 2001; 345: 1423.

Spencer R C Lightfoot N F . Preparedness and response to bioterrorism. J Infect 2001; 43: 104–110.